SUPPLEMENTAL TABLES
Supplemental Table 1. Methods for Identifying Comorbid Conditions
Condition / ICD-9 diagnosis code / ICD-9 procedure code / Disease registry / PharmacyDiabetes / *KPSC POINT system case identification criteria
Diabetes with end organ damage / 250.4-250.9
Anemia / 280-285
Hypertension / ≥2 outpatient diagnoses of hypertension (ICD-9 401-405), or
hypertension diagnosis from Health Connect significant health problem list / or
1 diagnosis + antihypertensive drug prescription for:
Calcium channel blockers
Beta adrenergic blockers
Antiadrenergics
Vasodilators
Ace Inhibitors
Antihypertensive combinations
Angiotensin antagonists
Loop Diuretics
Potassium sparing diuretics
Thiazide and related diuretics
Combinations diuretics
Renin inhibitors
Myocardial Infarction / 410, 412
Congestive heart failure / 428
Peripheral vascular disease / 440.2, 443.1, 443.8, 443.9, 441, 785.4, v43.4 / 38.13, 38.14, 38.16, 38.18, 38.33, 38.34, 38.36, 38.38, 38.43, 38.44, 38.46, 38.48, 39.22, 39.23, 39.24, 39.25, 39.26, 39.28, 39.29
Cerebrovascular disease / 430-438 / 38.12, 38.42
Thrombosis / 437.6, 453, 671.5, 671.9
COPD/
emphysema / 490-496, 500-505, 506.4
Previous cancer / 140-208 / Cancer registry
Liver disease / 571-572, 456.0-456.21
Renal disease / 582, 583, 585-588
Rheumatoid diseasea / 714, 725
Other autoimmune conditionsb / 340, 695.4, 710.0
Thyroid disorder (including autoimmune thyroiditis) / 240-246
Peptic ulcer disease / 531-534
Dementia / 290
Osteoarthritis / 715
Connective tissue diseasec / 710-714
HIV infection / HIV registry
AIDS / HIV registry
a Rheumatoid disease includes rheumatoid arthritis and polymyalgia rheumatica.
b Other autoimmune conditions includes systemic lupus erythematosus and multiple sclerosis.
c Connective tissue disease includes polyarteritis nodosa and other disorders of arteries and arterioles, diffuse diseases of connective tissues, rheumatoid arthritis and other inflammatory polyarthropathies.
HIV: human immunodeficiency virus; AIDS: acquired immune deficiency virus.
1
Supplemental Table 2. Sensitivity analysis adjusting for year of cancer diagnosis and clustering of cancer treatment medical centers
FN / Grade 3/4 neutropenia / Grade 4 neutropeniaHRa / 95% CI / HRa / 95% CI / HRa / 95% CI
Anemia / 0.91 / 0.42–1.71 / 1.01 / 0.73–1.37 / 0.96 / 0.62–1.43
Diabetes / 0.78 / 0.55–1.10 / 0.93 / 0.79–1.08 / 0.82 / 0.66–1.01
Diabetes with end organ damage / 0.71 / 0.41–1.17 / 0.72 / 0.54–0.93 / 0.74 / 0.51–1.03
Diabetes with treatment / 0.70 / 0.45–1.06 / 0.84 / 0.70–1.02 / 0.75 / 0.57–0.96
Diabetes with HbA1C ≤6.5% / 0.75 / 0.42–1.26 / 1.15 / 0.91–1.44 / 1.03 / 0.75–1.38
Diabetes with HbA1C >6.5% / 0.66 / 0.40–1.03 / 0.83 / 0.67–1.02 / 0.71 / 0.52–0.94
Hypertension / 1.10 / 0.84–1.44 / 0.94 / 0.84–1.06 / 0.91 / 0.77–1.06
Hypertension with treatment / 1.27 / 0.96–1.67 / 0.95 / 0.84–1.08 / 0.89 / 0.75–1.06
Myocardial infarction / 0.76 / 0.13–2.47 / 1.10 / 0.54–1.98 / 1.29 / 0.54–2.57
Congestive heart failure / 3.26 / 1.43–6.43 / 0.87 / 0.43–1.56 / 1.19 / 0.53–2.28
Peripheral vascular disease / 1.71 / 0.51–4.22 / 1.57 / 0.84–2.65 / 1.55 / 0.69–2.99
Cerebrovascular disease / 0.66 / 0.11–2.09 / 0.43 / 0.15–0.92 / 0.29 / 0.05–0.90
Chronic obstructive pulmonary disease/emphysema / 1.33 / 0.89–1.90 / 0.99 / 0.81–1.20 / 0.95 / 0.73–1.22
Previous cancer / 3.57 / 1.27–7.81 / 1.18 / 0.57–2.14 / 0.86 / 0.27–2.01
Liver disease / 1.34 / 0.22–4.22 / 2.13 / 1.10–3.67 / 1.76 / 0.69–3.60
Renal disease / 1.00 / 0.48–1.89 / 0.66 / 0.41–0.99 / 0.70 / 0.38–1.17
Rheumatoid disease / 0.22 / 0.01–0.97 / 0.99 / 0.62–1.48 / 1.11 / 0.62–1.81
Rheumatoid disease with treatment / 0.30 / 0.02–1.34 / 0.98 / 0.57–1.55 / 1.04 / 0.52–1.84
Other autoimmune conditions / 0.77 / 0.11–2.78 / 1.47 / 0.70–2.67 / 1.26 / 0.45–2.77
Thyroid disorder / 1.32 / 0.90–1.89 / 1.20 / 1.00–1.43 / 1.19 / 0.94–1.50
Osteoarthritis / 1.56 / 1.06–2.22 / 1.16 / 0.95–1.40 / 1.03 / 0.79–1.32
Connective tissue disease / 0.67 / 0.21–1.56 / 1.06 / 0.71–1.50 / 1.01 / 0.60–1.59
a The hazard ratio (HR) was estimated using Cox models accounting for medical center clustering and adjusting for the comorbid condition propensity score and year of cancer diagnosis. All models to determine the propensity score included age, sex, race/ethnicity, length of KPSC membership, public insurance status, census block income level, and census block education level. Additional covariates for the propensity score were specific to the comorbid condition of interest and are listed as follows: anemia (peptic ulcer disease, previous cancer, renal disease); diabetes and diabetes with end organ damage (dyslipidemia, smoking, obesity, thyroid disease); hypertension (dyslipidemia, smoking, diabetes, obesity, myocardial infarction, thyroid disease); myocardial infarction (dyslipidemia, hypertension, smoking, diabetes, obesity); congestive heart failure (dyslipidemia, hypertension, smoking, diabetes, obesity, myocardial infarction, thyroid disease, chronic obstructive pulmonary disease /emphysema); peripheral vascular disease (dyslipidemia, hypertension, smoking, diabetes, obesity); cerebrovascular disease (dyslipidemia, hypertension, smoking, diabetes, obesity, congestive heart failure); chronic obstructive pulmonary disease/emphysema (smoking); previous cancer (dyslipidemia, smoking, diabetes, obesity, thyroid disease, autoimmune conditions); liver disease (dyslipidemia, diabetes); and renal disease (hypertension, diabetes, smoking, infection (inpatient), autoimmune conditions).
1